25
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Keynote review: phosphodiesterase-4 as a therapeutic target.

      1 , ,
      Drug discovery today
      Elsevier BV

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Cyclic AMP (cAMP) is a key second messenger in all cells. It is compartmentalized within cells and its levels are controlled, as a result of spatially discrete signaling cassettes controlling its generation, detection and degradation. Underpinning compartmentalized cAMP signaling are approximately 20 members of the phosphodiesterase-4 (PDE4) family. The selective inhibition of this family generates profound, functional effects and PDE4 inhibitors are currently under development to provide potential, novel therapeutics for the treatment of inflammatory diseases, such as asthma, chronic obstructive pulmonary disease and psoriasis, as well as treating depression and serving as cognitive enhancers. Here, we delineate the range of PDE4 isoforms, their role in signaling, their structural biology and related preclinical and clinical pharmacology.

          Related collections

          Author and article information

          Journal
          Drug Discov Today
          Drug discovery today
          Elsevier BV
          1359-6446
          1359-6446
          Nov 15 2005
          : 10
          : 22
          Affiliations
          [1 ] Division of Biochemistry and Molecular Biology, IBLS, Wolfson Link Building, University of Glasgow, University Avenue, Glasgow, G12 8QQ, Scotland, UK. m.houslay@bio.gla.ac.uk
          Article
          S1359-6446(05)03622-6
          10.1016/S1359-6446(05)03622-6
          16257373
          0d1414fa-720d-49ba-9213-8fb4aad6954b
          History

          Comments

          Comment on this article